​

Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?

OverviewForecastFinancialsChart

Enliven Therapeutics Ownership Summary

Enliven Therapeutics is owned by 102.81% institutional investors, 6.42% insiders. Capital advisors is the largest institutional shareholder, holding 0% of ELVN shares.

ELVN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEnliven Therapeutics102.81%6.42%-9.23%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Capital advisors---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Capital advisors---

Top Buyers

HolderShares% AssetsChange
Capital advisors---302.00

Top Sellers

HolderShares% AssetsChange
Capital advisors---302.00

Sold Out

HolderChange
Capital advisors-302.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20241129.80%49,623,7144.06%1021.05%6611.86%254.17%
Sep 30, 20241028.51%47,688,348-1.31%980.98%59-14.49%2484.62%
Jun 30, 20249430.56%48,320,2788.69%1000.90%6972.50%13-40.91%
Mar 31, 20247218.03%44,456,33613.99%1051.18%4029.03%2269.23%
Dec 31, 202361-1.61%39,000,634-0.19%941.05%316.90%13-40.91%

Recent Insider Transactions

DateNameRoleActivityValue
Apr 21, 2025Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICERSell$5.52K
Apr 21, 2025Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICERSell$74.85K
Apr 17, 2025Kintz Samuel PRESIDENT AND CEOSell$82.10K
Apr 07, 2025Patel Anish CHIEF OPERATING OFFICERSell$2.85K
Apr 07, 2025Patel Anish CHIEF OPERATING OFFICERSell$66.89K

Insider Transactions Trends

DateBuySell
2025 Q2-6
2025 Q1-14
2024 Q4-34
2024 Q3-27
2024 Q2-49

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 102.81%, followed by 6.42% insiders and -9.23% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 68.48%, which Enliven Therapeutics exceeds.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Capital advisors is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 0% of its assets in 0 Enliven Therapeutics shares, valued at 0$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools